Renovaro Biosciences Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was USD 39.68 million compared to USD 113.43 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 2.16 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | -2.07% | -3.40% | -55.21% |
May. 24 | Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy | MT |
May. 24 | Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy | CI |
1st Jan change | Capi. | |
---|---|---|
-55.21% | 214M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- RENB Stock
- News Renovaro Inc.
- Renovaro Biosciences Inc. Reports Earnings Results for the Full Year Ended June 30, 2023